Reference is made to the stock exchange release from SoftOx Solutions AS (the
"Company") on 11 March 2026 regarding the board resolution to increase the share
capital by carrying out a private placement of NOK 3 600 000 under the financing
facility with the investment fund Long State Investments Limited ("Long State").
The new share capital, following completion of the private placement, has today
been registered with the Norwegian Register of Business Enterprises.
The new share capital of the Company is NOK 49 908 339.88 divided into 2 495 416
994 shares, each with a par value of NOK 0.02.
For more information on the financing facility, please see the Company's stock
exchange release dated 14 September 2025.
For further information, please contact:
Ulrik Spork, COB Soft Solutions AS, +45 31 38 83 87
Ingrid Juven, CFO SoftOx Solutions AS, +47 918 76 165
Mail: ir@soft-ox.com
About SoftOx Solutions AS:
SoftOx Solutions AS (ticker: SOFTX) is a clinical-stage pharmaceutical company
listed on Euronext Growth Oslo. The company is developing highly effective
pan-antimicrobial pharmaceuticals targeting bacteria, viruses, and fungi. The
technology is based on extensive research and development in partnership with
leading Nordic research institutes.